Home
Companies
Catalysts
Deep Dives
Nemtabrutinib
MK-1026
PHASE3
Drug Profile
Modality
Small molecule
Route
PO
Therapy Area
Oncology
Peak Sales Est
$1500M
Formulations
[]
Companies
MRK
(ORIGINATOR)
100%
Mechanism: BTK inhibitor
Expert:
Selective covalent inhibitor of Bruton's tyrosine kinase that disrupts B-cell receptor signaling critical for CLL and MCL survival.
Everyday:
Blocks a protein that B-cell cancers need to survive and grow.
Targets: ["BTK"]
Notes
Non-covalent BTK inhibitor. For CLL/SLL resistant to covalent BTKis.
Data from Supabase · Updated 2026-03-24